European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer
Daniela E. Oprea‐Lager(Amsterdam University Medical Centers), Stefano Fanti(Azienda USL di Bologna), Jolanta Kunikowska(Medical University of Warsaw), Karim Fizazi(Université de Lille), Silke Gillessen(Institute of Oncology Research), Andrei Iagaru(Stanford University), Igle J. de Jong(University of Groningen), Anders Bjartell(Lund University), Valeria Panebianco(Sapienza University of Rome), Rudi Dierckx(University Medical Center Groningen), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Jochen Walz(Institut Paoli-Calmettes), Marnix G. E. H. Lam(University Medical Center Utrecht), Evis Sala(Università Cattolica del Sacro Cuore), Mike Sathekge(Steve Biko Hospital), Derya Tilki(Koç University), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Irene A. Burger(University of Zurich), Joe M. O’Sullivan(San Antonio College), Sandra Heskamp(Radboud University Nijmegen), Barbara Alicja Jereczek‐Fossa(European Institute of Oncology), Nina Tunariu(Leicester Royal Infirmary), Louise Emmett(St Vincent's Hospital Sydney), Cristina Nanni(Azienda USL di Bologna), Derya Yakar(Dialyse Centrum Groningen), Oliver Sartor(Mayo Clinic), Roman Sosnowski(National Institute of Oncology), Uta Eberlein(University of Würzburg), Steven MacLennan(University of Aberdeen), Giorgio Treglia(Ente Ospedaliero Cantonale), Maria De Santis(Medical University of Vienna), Ken Herrmann(Essen University Hospital)
Cited by 46
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k